文献速递妇科肿瘤支持与姑息治疗

盆腔IMRT对宫颈癌和子宫内膜癌患者报告的急性毒性:NRG Oncology/RTOG 1203

Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.
PubMed 文献 · J Clin Oncol · 2018-07-10

NRG Oncology/RTOG 1203比较了标准盆腔放疗与IMRT在宫颈癌和子宫内膜癌患者中的患者报告急性毒性和健康相关生活质量。从基线至放疗结束,IMRT组EPIC肠道评分下降18.6分,标准放疗组下降23.6分(P=.048);IMRT组EPIC泌尿评分下降5.6分,标准放疗组下降10.4分(P=.03)。结论:从患者角度看,盆腔IMRT与标准放疗相比,胃肠道和泌尿毒性显著更少。

要点

  • IMRT组患者报告的肠道毒性下降幅度显著小于标准放疗组
  • IMRT组患者报告的泌尿毒性下降幅度显著小于标准放疗组
  • IMRT组频繁或几乎持续腹泻及每日使用止泻药≥4次的比例更低

核心结论

  • 从患者角度评估,盆腔IMRT与标准放疗相比,急性胃肠道和泌尿毒性显著更少。

研究设计与样本

  • 随机对照试验,2012年至2015年纳入289例宫颈癌和子宫内膜癌患者,其中278例符合分析条件。
  • 患者随机分配至标准四野放疗或IMRT。
  • 主要终点为基线至放疗结束时EPIC肠道域评分的改变。

主要发现

  • EPIC肠道评分平均下降:标准放疗组23.6分,IMRT组18.6分(P=.048)。
  • EPIC泌尿评分平均下降:标准放疗组10.4分,IMRT组5.6分(P=.03)。
  • 试验结局指数评分平均下降:标准放疗组12.8分,IMRT组8.8分(P=.06)。
  • 放疗结束时,标准放疗组51.9%和IMRT组33.7%报告频繁或几乎持续腹泻(P=.01)。
  • 标准放疗组20.4%和IMRT组7.8%每日使用止泻药≥4次(P=.04)。

临床怎么用

  • 对于接受盆腔放疗的宫颈癌和子宫内膜癌患者,可优先考虑IMRT以减轻患者报告的急性胃肠道和泌尿毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose NRG Oncology/RTOG 1203 was designed to compare patient-reported acute toxicity and health-related quality of life during treatment with standard pelvic radiation or intensity-modulated radiation therapy (IMRT) in women with cervical and endometrial cancer. Methods Patients were randomly assigned to standard four-field radiation therapy (RT) or IMRT radiation treatment. The primary end point was change in patient-reported acute GI toxicity from baseline to the end of RT, measured with the bowel domain of the Expanded Prostate Cancer Index Composite (EPIC). Secondary end points included change in patient-reported urinary toxicity, change in GI toxicity measured with the Patient-Reported Outcome Common Terminology Criteria for Adverse Events, and quality of life measured with the Trial Outcome Index. Results From 2012 to 2015, 289 patients were enrolled, of whom 278 were eligible. Between baseline and end of RT, the mean EPIC bowel score declined 23.6 points in the standard RT group and 18.6 points in the IMRT group ( P = .048), the mean EPIC urinary score declined 10.4 points in the standard RT group and 5.6 points in the IMRT group ( P = .03), and the mean Trial Outcome Index score declined 12.8 points in the standard RT group and 8.8 points in the IMRT group ( P = .06). At the end of RT, 51.9% of women who received standard RT and 33.7% who received IMRT reported frequent or almost constant diarrhea ( P = .01), and more patients who received standard RT were taking antidiarrheal medications four or more times daily (20.4% v 7.8%; P = .04). Conclusion Pelvic IMRT was associated with significantly less GI and urinary toxicity than standard RT from the patient's perspective.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Klopp AH, Yeung AR, Deshmukh S, et al. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018. PMID: 29989857. doi:10.1200/JCO.2017.77.4273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。